Blood Reviews
Volume 23 , Pages S3-S7 , December 2009

Optimizing iron chelation strategies in β-thalassaemia major

  • John B. Porter

      Affiliations

    • Corresponding Author InformationCorrespondence: John B. Porter, MA, MD, FRCP, FRCPath. Department of Haematology, University College London, UCL Cancer Institute, Paul O'Gorman Building, 72 Huntley Street, London, WC1E 6BT, UK. Tel.: +44 207 679 6224; fax: +44 207 679 6222

References 

  1. Anderson LJ , Holden S , Davis B , et al.   Cardiovascular T2-star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload . Eur Heart J . 2001;22:2171–2179
  2. Patton N , Brown G , Leung M , et al.   Observational study of iron overload as assessed by magnetic resonance imaging (MRI) in an adult population of transfusion dependent patients with beta thalassaemia: signiFIcant association between low cardiac T2* <10 ms and the occurrence of cardiac events . Intern Med J . 2009; [Epub ahead of print].
  3. Kirk P , Roughton M , Porter JB , et al.   Cardiac T2* magnetic resonance for prediction of cardiac complications in thalassemia major . J Cardiovasc Magn Reson . 2009;11(Suppl 1):O2
  4. Borgna-Pignatti C , Rugolotto S , De Stefano P , et al.   Survival and complications in patients with thalassaemia major treated with transfusion and deferoxamine . Haematologica . 2004;89:1187–1193
  5. Cohen AR , Glimm E , Porter JB . Effect of transfusional iron intake on response to chelation therapy in β-thalassemia major . Blood . 2008;111:583–587
  6. Cabantchik ZI , Breuer W , Zanninelli G , et al.   LPI-labile plasma iron in iron overload . Best Pract Res Clin Haematol . 2005;18:277–287
  7. Daar S , Pathare A , Nick H , et al.   Reduction in labile plasma iron during treatment with deferasirox, a once-daily oral iron chelator, in heavily iron-overloaded patients with β-thalassaemia . Eur J Haematol . 2009;82:454–457
  8. Wonke B , Wright C , Hoffbrand AV . Combined therapy with deferiprone and desferrioxamine . Br J Haematol . 1998;106:252–253
  9. Piga A , Roggero S , Vincinguerra T , et al.   Deferiprone: new insight . Ann NY Acad Sci . 2005;1054:169–174
  10. Peng CT , Wu KH , Wu SF , et al.   Deferiprone or deferoxamine vs. combination therapy in patients with beta-thalassemia major: a case study in Taiwan . Hemoglobin . 2006;30:125–130
  11. Kolnagou A , Kontoghiorghes GJ . Effective combination therapy of deferiprone and deferoxamine for the rapid clearance of excess cardiac iron and the prevention of heart disease in thalassaemia. The Protocol of the International Committee on Oral Chelators . Hemoglobin . 2006;30:239–249
  12. Daar S , Pathare AV . Combined therapy with desferrioxamine and deferiprone in beta thalassaemia major patients with transfusional iron overload . Ann Hematol . 2006;85:315–319
  13. Mourad FH , Hoffbrand AV , Sheikh-Taha M , et al.   Comparison between desferrioxamine and combined therapy with desferrioxamine and deferiprone in iron overloaded thalassaemia patients . Br J Haematol . 2003;121:187–189
  14. Gomber S , Saxena R , Madan N . Comparative efFIcacy of desferrioxamine, deferiprone and in combination on iron chelation in thalassemic children . Indian J Pediatr . 2004;41:21–27
  15. Galanello R , Kattamis A , Piga A , et al.   A prospective randomized controlled trial on the safety and efFIcacy of alternating deferoxamine and deferiprone in the treatment of iron overload in patients with thalassaemia . Haematologica . 2006;91:1241–1243
  16. Aydinok Y , Ulger Z , Nart D , et al.   A randomized controlled 1-year study of daily deferiprone plus twice weekly desferrioxamine compared with daily deferiprone monotherapy in patients with thalassaemia major . Haematologica . 2007;92:1599–1606
  17. Tanner MA , Galanello R , Dessi C , et al.   A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassaemia major using cardiovascular magnetic resonance . Circulation . 2007;115:1876–1884
  18. Tanner MA , Galanello R , Dessi C , et al.   Combined chelation therapy in thalassaemia major for the treatment of severe myocardial siderosis with left ventricular dysfunction . J Cardiovasc Magn Reson . 2008;25:12
  19. El-Beshlawy A , Manz C , Naja M , et al.   Iron chelation in thalassaemia: combined or monotherapy? The Egyptian experience . Ann Hematol . 2008;87:545–550
  20. Maggio A , Vitrano A , Capra M , et al.   Improving survival with deferiprone treatment in patients with thalassemia major: a prospective multicenter randomised clinical trial under the auspices of the Italian Society for Thalassemia and Hemoglobinopathies . Blood Cells Mol Dis . 2009;42:247–251
  21. Olivieri NF , Brittenham GM . Iron-chelating therapy and the treatment of thalassaemia . Blood . 1997;89:736–761
  22. Guidelines for the clinical management of thalassaemia. 2nd edition; 2007.
  23. Cappellini MD , Galanello R , Piga A , et al.   EfFIcacy and safety of deferasirox (Exjade®) with up to 4.5 years of treatment in patients with thalassemia major: a pooled analysis . Blood . 2008;112: abstract 5411.
  24. Porter JB , Piga A , Cohen A , et al.   Safety of deferasirox (Exjade®) in patients with transfusion-dependent anaemias and iron overload who achieve serum ferritin levels <1000 ng/ml during long-term treatment . Blood . 2008;112: abstract 5423.
  25. Piga A , Forni GL , Kattamis A , et al.   Deferasirox (Exjade®) in pediatric patients with β-thalassemia: update of 4.7 year efFIcacy and safety from extension studies . Blood . 2008;112: abstract 3883.
  26. Piga A , Kebaili K , Galanello R , et al.   Cumulative efFIcacy and safety of 5-year deferasirox (Exjade®) treatment in pediatric patients with thalassemia major: a phase II multicenter prospective trial . Blood . 2008;112: abstract 5413.
  27. Taher A , El-Beshlawy A , Elalfy MS , et al.   EfFIcacy and safety of deferasirox, an oral iron chelation, in heavily iron-overloaded patients with β-thalassaemia: the ESCALATOR study . Eur J Haematol . 2009;82:458–465
  28. Taher A , Cappellini MD , Vichinsky E , et al.   EfFIcacy and safety of deferasirox doses of >30 mg/kg per d in patients with transfusion-dependent anaemia and iron overload . Br J Haematol . 2009;147(5):752–759
  29. Cappellini MD , Porter JB , El-Beshlawy A , et al.   Tailoring iron chelation by iron intake and serum ferritin: prospective EPIC study of deferasirox in 1744 patients with transfusion-dependent anemias . Haematologica . 2009; [Epub ahead of print].
  30. Porter JB , Cappellini MD , El-Beshlawy A , et al.   Effect of deferasirox (Exjade®)on labile plasma iron levels in heavily iron-overloaded patients with transfusion- dependent anemias enrolled in the large-scale, prospective 1-year EPIC trial . Blood . 2008;112: abstract 3881.
  31. Pennell D , Porter JB , Cappellini MD , et al.   EfFIcacy and safety of deferasirox (Exjade®) in reducing cardiac iron in patients with β-thalassemia major: results from the Cardiac Substudy of the EPIC trial . Blood . 2008;112: abstract 3873.
  32. Pennell D , Sutcharitchan P , El-Beshlawy A , et al.   EfFIcacy and safety of deferasirox (Exjade®) in preventing cardiac iron overload in β-thalassemia patients with normal baseline cardiac iron: results from the Cardiac Substudy of the EPIC trial . Blood . 2008;112: abstract 3874.
  33. Wood JC , Thompson AA , Paley C , et al.   Deferasirox (Exjade®) monotherapy signiFIcantly reduces cardiac iron burden in chronically transfused β-thalassemia patients: an MRI T2* study . Blood . 2008;112: abstract 3882.

PII: S0268-960X(09)70003-7

doi: 10.1016/S0268-960X(09)70003-7

Blood Reviews
Volume 23 , Pages S3-S7 , December 2009

Article Tools